



PRESS KIT

CAMPTON DIAGNOSTICS GMBH

COMPANY PROFILE

About CAMPTON Diagnostics GmbH

CAMPTON Diagnostics GmbH was spun off from the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe in 2016.

The company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. CAMPTON Diagnostics combines biotechnological and engineering know-how under one roof.

The "Biochip Reader" device developed by CAMPTON uses silicon-based biochips from Fraunhofer ISIT. The ISIT produces these in the institute's own clean room.

The system, which is based on "electrical biochip technology", can be used to obtain reliable information on the indication of infections, cancer or other diseases made from a small amount of whole blood within a few minutes. The tests are particularly fast, highly sensitive and enable the simultaneous measurement of several parameters in one sample.

Disposable cartridges with an integrated biochip are used for the measurements. The biochip functions like a conventional ELISA test, but is electrically readable and therefore extremely miniaturizable. The "Biochip Reader" performs the measurement fully automatically. After a few minutes, the analysis result is shown on the display as a real value.

CAMPTON Diagnostics is based in Itzehoe and has a strategic technology partnership with the Fraunhofer Institute for Silicon Technology (ISIT).

Further information can be found at www.campton-diagnostics.com.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743
E-Mail: pressestelle@marvice.de

FACTS & FIGURES

Year of foundation:	2016
Management:	Jürgen Brink (CEO) Dr. Eric Nebling (CSO) Lars Blohm (CTO)
Associates	Jürgen Brink Dr. Eric Nebling Lars Blohm Jörg Albers DDr. Karl Gollegger Adolf Würth GmbH & Co. KG
Advisory council	DDr. Karl Gollegger Alexander Gerfer Dr. Axel Müller-Groeling Niels Ahlmann-Ohlsen
Business divisions:	Point-of-care diagnostics: <ul style="list-style-type: none"> • Human diagnostics <p>Further possible areas of application:</p> <ul style="list-style-type: none"> • Veterinary Diagnostics • Food diagnostics
Employees:	The establishment of an interdisciplinary team for the certified development and manufacture of medical products at the Itzehoe site is in progress. Current number of employees: 5 (approx. 9 by the end of 2019)
Corporate philosophy:	Improve patient care and treatment through point-of-care diagnostics to identify cancer, infectious and autoimmune diseases in doctors' offices, hospitals and clinics worldwide.
Technology partner:	Fraunhofer ISIT, Itzehoe
Production site:	Itzehoe

FACTS & FIGURES

Products: Campton Biochip Reader 100

Further generations in planning:

- Campton Biochip Reader 250 (mobile technology)
- Campton Biochip Reader 300 (smartphone-controlled technology)

Areas of application: With just one drop of blood, reliable, rapid analyses can be performed for many different diseases, for example:

- Allergies (food allergies, environmental allergies)
- Infectious diseases (borreliosis, malaria, ebola, hepatitis, HIV, zika, etc.)
- Oncology (early detection of cancer, therapy monitoring)
- autoimmune diseases
- cardiovascular diseases

The use of the biochip system is not limited to the diseases mentioned above.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743

E-Mail: pressestelle@marvice.de

MANAGEMENT PROFILES

Jürgen Brink **CEO**

Mr. Brink is a founding partner of CAMPTON Diagnostics and is responsible within the company for sales, finance, legal, human resources and IT.

Since 2006, Mr. Brink has been a managing partner of the management consultancy brink.corporate development GmbH, which specializes in corporate strategy, mergers and acquisitions (M&A) and financing with equity and debt capital.

Prior to this, Mr. Brink was responsible for projects in the areas of "acquisition and project financing, M&A transactions and IPO consulting" as project manager in various banks and an international auditing company for many years, before he was able to develop a portfolio of approx. 500 companies worldwide as Director Corporate Development/M&A of one of the larger German family-owned companies.

Lars Blohm **CTO / Technical Director**

After training as an industrial electronics engineer and studying electrical engineering, Lars Blohm joined eBiochip Systems GmbH in 2002 as an engineer, where he developed automated analytical systems with electrical biochips.

From 2009 to 2019 he worked as a scientist at the Fraunhofer Institute for Silicon Technology (ISIT). As project manager of public and industrial projects, he was particularly involved in the development and construction of integrated complete systems for biomedical and energy-efficient MEMS applications.

Since June 2019, he has been a founding partner of CAMPTON Diagnostics, where he is full-time Managing Director and Technical Director (CTO). Currently, he is responsible for the certified development, manufacture and marketing of medical systems for point-of-care diagnostics at CAMPTON Diagnostics.

MANAGEMENT PROFILES

Dr. Eric Nebling
CSO / Scientific Director

Dr. Eric Nebling studied chemistry in Hamburg and subsequently received his doctorate in biochemistry.

Since 1999 he was employed at the Fraunhofer Institute for Silicon Technology (ISIT) in the department "Biotechnical Microsystems" (BTMS) and worked on the development and optimization of biochemical test methods on electrical biochips. Dr. Nebling was responsible for various research projects and had been head of the department since 2008.

He is co-founder of CAMPTON Diagnostics GmbH and scientific director (CSO) of the company. Since June 2019, Dr. Nebling has been working full-time for CAMPTON Diagnostics GmbH.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743
E-Mail: pressestelle@marvice.de

PRODUCT INFORMATION

CAMPTON Biochip Reader

The *CAMPTON Biochip Reader* takes POC diagnostics to the next level of laboratory testing and heralds a new era of mobile diagnostics. Using a small amount of whole blood, our biochip reader provides reliable rapid analyses for many different diseases.

CAMPTON biochip readers help to improve patient care and treatment.

POC Diagnostics

Scientists at the *Fraunhofer Institute for Silicon Technology (ISIT)* have developed a new point-of-care (POC) technology to identify cancer, infectious and autoimmune diseases in medical practices, hospitals and clinics worldwide.

POC diagnostics is a decentralised, patient-oriented test that is usually carried out with portable devices. These tests provide rapid results to improve patient care and treatment.

The system solution is certified, produced and sold worldwide by *CAMPTON Diagnostics*. The relevant technology is patented by *Fraunhofer* and exclusively licensed worldwide by *CAMPTON Diagnostics*.

The advantages of the CAMPTON Biochip Reader System

The detection of biomarkers in a blood sample from patients is currently based on immunological tests ("Enzyme-Linked ImmunoSorbent Assay" [ELISA] and "Recombinant Immunoblot Assay" [RIA]). These tests usually require laboratories, trained staff and are time-consuming (hours to days to obtain results).

Portable diagnostic devices such as the *CAMPTON Biochip Reader* offer a much faster test result, which is very advantageous in the field of medical care. The advantage of the system for the end customer (as well as for our direct customers, doctors and hospitals) is that it is less expensive and takes less time. It takes less than 15 minutes to perform the test and obtain the results.

The system is deliberately designed to use various biological substances to identify the relevant diseases. Competitors often use optical systems to identify the diseases, while the newly developed CAMPTON technology uses electrical signals. This means that CAMPTON technology is more robust and suitable for use in almost any climate.

PRODUCT INFORMATION

The Technology

In addition to the wide range of possible customer-specific applications, the following tests are currently available for research and development

- SARS-CoV-2 (serological and molecular biological, from 2021)
- Vaccination status (serological)
- CRP (serological)
- Customised tests

Selected examples of diseases that can be diagnosed with the CAMPTON Biochip System are

- Allergies
- Infectious diseases (such as malaria, Ebola, HCV, HIV, Zika virus)
- Multiple Sclerosis
- Blood cancer / leukaemia
- Prostate cancer and other diseases

The use of the biochip system is not limited to the above mentioned diseases. It is possible to integrate almost any ELISA-based test into the biochip platform as long as disease-specific proteins can be found in any kind of body fluid.

Press contact

Karin van Soest-Schückhaus
marvice GmbH
Mobile: 0172- 2524 845
Phone: 02161-8269743
e-mail: pressestelle@marvice.de